News Sanofi

Stocks

SAN

FR0000120578

Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 18:55:00 17/06/2026 +03			5-day change	1st Jan Change
74.88 ^EUR	-1.03%		-1.49%	-9.48%

06-17	European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading	MT
06-17	Medpace: At the Heart of the Small-Cap Biopharma Crisis

All News

Mentions Relevance

06-15	Sanofi Says US FDA Approved Tzield for Recently Diagnosed Stage 3 Type 1 Diabetes in Children	MT
06-15	SANOFI : Gets a Buy rating from Deutsche Bank	ZD
06-15	Sanofi Secures Accelerated Approval in Diabetes
06-15	Sanofi Wins US Approval for Disease-modifying Therapy for Diabetes in Children	MT
06-13	Sanofi - Shareholder/Analyst Call
06-13	Sanofi Receives Accelerated Approval for Tzield as First Disease-Modifying Therapy for Stage 3 Type 1 Diabetes	CI
06-13	FDA approves expanded use of Sanofi's type 1 diabetes drug	RE
06-13	Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes	GL
06-13	FDA approves Sanofi's drug for stage 3 type 1 diabetes in children	RE
06-12	Sanofi's Tzield Receives FDA Approval for Diabetes Treatment	DJ
06-10	CIC Corp. & Institutional Banking Trims Sanofi PT, Keeps Buy Rating	MT
06-10	Sanofi Provides Update On Mobilize Phase 3 Study Of Riliprubart In Chronic Inflammatory Demyelinating Polyneuropathy	CI
06-10	Sanofi Terminates Late-stage Trial for Rare Neurological Disorder Treatment; 2026 Guidance Maintained	MT
06-10	Sanofi Stops Late-Stage Trial of Autoimmune Disease Therapy After Interim Review	MT
06-10	Sanofi ends Phase 3 riliprubart trial after weak interim results	RE
06-10	Sanofi to Stop Late-Stage Study of Immune-Disorder Drug	DJ
06-10	Sanofi halts Phase 3 study in CIDP
06-10	Sanofi to Discontinue Late-stage Trial of Riliprubart in Rare Neurological Disorder	MT
06-10	Sanofi provides update on MOBILIZE phase 3 study of riliprubart in chronic inflammatory demyelinating polyneuropathy	GL
06-09	SANOFI : Deutsche Bank remains its Buy rating	ZD
06-08	Sanofi Receives European Commission Approval For Sarclisa Subcutaneous As First Anticancer Treatment Administered Via On-Body Injector	CI
06-08	Sanofi's Subcutaneous Sarclisa Approved in EU Across Multiple Myeloma Indications	MT
06-08	Sanofi Wins EU Approval for Subcutaneous Sarclisa in Multiple Myeloma	MT
06-08	Brussels greenlights subcutaneous administration for Sanofi's Sarclisa
06-08	Sanofi’s Sarclisa subcutaneous approved in the EU as the first anticancer treatment administered via an on-body injector	GL